Bristol Myers scales up cell therapy production with liso-cel nod in hand and another approval maybe on the way

Kyle Blankenship

After a long-awaited approval for its CD19 targeting CAR-T liso-cel, Bristol Myers Squibb is gearing up for the looming review of another cell therapy in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bristol Myers scales up cell therapy production with liso-cel nod in hand and another approval maybe on the way

Kyle Blankenship

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Bris­tol My­ers scales up cell ther­a­py pro­duc­tion with liso-cel nod in hand and an­oth­er ap­proval maybe on the way

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Bristol Myers scales up cell therapy production with liso-cel nod in hand and another approval maybe on the way